Efficacy and safety evaluation of type‐3 phosphodiesterase inhibitor Cilostazol in mild cognitive impairment
Satoshi Saito, Haruko Yamamoto, Masanori Fukushima, Masafumi Ihara, the COMCID Trial Investigator Group · 2025
Read Efficacy and safety evaluation of type‐3 phosphodiesterase inhibitor Cilostazol in mild cognitive impairment by Satoshi Saito, Haruko Yamamoto, Masanori Fukushima, Masafumi Ihara, the COMCID Trial Investigator Group (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712677.txt.
Description
Satoshi Saito and co-authors, with a trial group, test the drug cilostazol in mild cognitive impairment in a 2025 paper. The drug blocks a set enzyme and, by a drainage path in the brain, helps clear beta-amyloid, the protein that builds up in Alzheimer's disease.
Patients were split at random, in a blind trial at many centers, between the drug and a placebo. The main score was a standard test of mental state. Mind tests and blood levels of an amyloid form were read as well. No grave side effects came from the drug. The main and side scores did not set the drug apart.
Catalog record
| CREATOR | Satoshi Saito, Haruko Yamamoto, Masanori Fukushima, Masafumi Ihara, the COMCID Trial Investigator Group |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 1 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |